Scioderm
1007 Slater Road
Suite 170
Durham
North Carolina
27703
United States
Tel: 919-328-2020
Website: http://www.sderm.com/
Email: info@sderm.com
About Scioderm
Scioderm is a biopharmaceutical company focused on developing innovative therapies for treating diseases with high unmet need, including orphan products.Our lead product, SD-101, is being developed for treatment of the skin effects associated with Epidermolysis Bullosa (EB), which is a rare genetic connective tissue disorder. There are many genetic and symptomatic variations of EB, but all share the prominent symptom of extremely fragile skin that blisters and tears from minor friction or trauma. Internal organs and bodily systems can also be seriously affected by the disease.
The skin is one of the most effective barriers in the body to prevent penetration of pharmaceuticals, which has been the primary reason for the difficulty in development of locally effective topical therapies. The key to a successful topical product is not only the active moiety but also having a formulation to effectively deliver the active ingredient across the various skin barriers. The SD-101 unique proprietary formulation has been shown to deliver the active ingredient across various skin penetration models in a dose dependent manner.
25 articles about Scioderm
-
Amicus Completes Acquisition Of Scioderm
9/30/2015
-
Amicus Snaps up Scioderm and its Lead EB Drug in Deal Worth $847 Million
8/31/2015
-
Scioderm To Submit Rolling NDA To U.S. FDA For Zorblisa
7/14/2015
-
Scioderm Initiates Phase 3 Registration Trial Of Zorblisatm (SD-101), A Novel Topical Therapy For Patients With Epidermolysis Bullosa
3/19/2015
-
Scioderm Appoints Ian A. W. Howes Chief Financial Officer
1/6/2015
-
Scioderm To Present At 33rd Annual J.P. Morgan Healthcare Conference
1/2/2015
-
Scioderm Locks In $20 Million Series B
12/18/2014
-
Scioderm, Inc. To Present Data From Phase 2b Study Of Zorblisa™ (SD-101) At The 13th Annual Scioderm Investor Forum
10/6/2014
-
Scioderm To Present Data From Phase 2b Study Of Zorblisa™ (SD-101) At The Debra International Congress
9/9/2014
-
Scioderm Names Ronald Nardi, Ph.D. Chief Scientific Officer
6/12/2014
-
Scioderm Receives Orphan Drug Designation In The European Union For Novel Topical Therapy To Treat Epidermolysis Bullosa
1/23/2014
-
Scioderm To Present At 32nd Annual J.P. Morgan Healthcare Conference
1/7/2014
-
Scioderm Initiates Phase 2B Study Of SD-101, A Novel Topical Therapy, For Patients With Epidermolysis Bullosa
1/6/2014
-
Scioderm Receives Positive Opinion From European Orphan Medicinal Products Committee For Novel Topical Therapy To Treat Epidermolysis Bullosa
12/17/2013
-
Scioderm Appoints Orphan Product Executives To Board Of Directors
12/2/2013
-
Scioderm Honored With Partners in Progress Award From DEBRA of America
10/30/2013
-
Scioderm's CEO Dr. Robert Ryan Appointed Member of DebRA Board
10/21/2013
-
Novella Clinical Selected by Scioderm to Manage Rare Disease Study
10/15/2013
-
Scioderm to Present at Biotechnology Industry Organization (BIO)-Europe 2013 Conference
10/14/2013
-
Scioderm's SD-101 Receives Breakthrough Therapy Designation From FDA for Treatment of Epidermolysis Bullosa
5/6/2013